The American Society of Clinical Oncology (ASCO) is the largest and most influential organization of oncology societies in the world. Every ASCO annual meeting attracts big names. This year's ASCO annual meeting will be held from June 4th to June 8th, local time. Many top experts in the field of oncology will share with the participants on tumor clinical research and future development. Chinese experts and scholars also shared 35 tumor-related studies at the conference, including 3 Clinical Science Symposium, 15 Oral Abstract Session (oral report), and 17 Poster Discussion Session. Among them, there are 6 reports related to the field of CAR cell therapy.

The clinical research results of Chongqing Precision Biotech and the team of Director Wang Sanbin of the 920th Hospital of the Chinese People's Liberation Army Joint Logistics Support Force have been selected for the Clinical Science Symposium, and an oral report will be given at 9:48 on June 6th, Beijing time. The speaker is Dr. Li Shiqi. (https://meetings.asco.org/2022-asco-annual-meeting/14337?presentation=214050#214050). After the report, there is also NIH expert Professor Jeremy Mark Pantin's discussion and commentary on this report. Stay tuned!

Autologous CD19-directed CAR T cells produced bynovel PrimeCAR manufacture platform exhibit safety, efficacy, and longpersistence profiles in relapsed/refractory  B-lineage acute leukemia (r/rB-ALL).

Presenter: Shiqi Li, MD, PhD | 920th Hospital ofJoint Logistics Support Force of People's Liberation Army of China

Abstract: 7008

In order to solve the problem of CAR-T side reactions and high production costs, Chongqing Precision Biotech has developed the PrimeCARTM cell preparation process, which can effectively reduce the side effects caused by treatment and propose a "precise" solution for the improvement of CAR-T. Chongqing Precision Biotech cooperated with the team of Director Wang Sanbin of the 920th Hospital of the Chinese People's Liberation Army Joint Logistics Support Force to carry out clinical research on various hematological tumors including acute lymphoblastic leukemia, lymphoma and multiple myeloma using the PrimeCARTM cell preparation process , the results show that the PrimeCARTM cell preparation process can effectively reduces the toxic and side effects of patients, while improving the therapeutic effect .

The report selected for the ASCO Annual Meeting Clinical Science Symposium is titled "AutologousCD19-directed CAR T cells produced by novel PrimeCAR manufacture platformexhibit safety, efficacy, and long persistence profiles in relapsed/refractoryB-lineage acute leukemia (r/r B-ALL)”.It is the research result of acute lymphoblastic leukemia, and the follow-up research results of more indications will be published in the form of conferences or articles.